General Comments / Chat, page-10410

Great to see DCB still quite supportive of RAC, having reposted the vacant scientist position to his extensive network.

I had a flick through the job description last night, a quick shoutout to Dr. T for including a salary range in the job posting, massive pet peeve of mine when salaries expectations are hidden by employers.

Now, if it pleases the court of members of this forum, allow me to indulge myself in a little unqualified opinion and unbridled speculation. It is after all what this board is so good at.

I couldn't help but notice the job description laboring on about a specific segment of the drug development process: preclinical activities. See Below:


Now maybe I am just reading in to this way too much. But with P1 RC-220 trials expected to get underway in H2 of this year, why bring on permanent staff with such a focus on preclinical drug development. I would assume that most of the preclinical studies for bisantrene/RC 220 are already underway and hopefully nearing completion.

Unless of course, the NMR collaboration with Monash has borne some sweet fruit which may require the evaluation of its preclinical characteristics. We know the program is ongoing, and sweet FA has been spoken of it publicly in quite some time. Of course the results of this program would be highly commercially sensitive which would explain the radio silence.

Does RAC have a little sibling for bisantrene? Or did I over indulge on red wine last night? Or both?